{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:49:22Z","timestamp":1776703762137,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00428-022-03322-7","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T10:03:30Z","timestamp":1649930610000},"page":"93-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis"],"prefix":"10.1007","volume":"481","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-4229","authenticated-orcid":false,"given":"Andrea","family":"Ambrosini-Spaltro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Limarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Calpona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Meccariello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"3322_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR et al (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primer 6:92. https:\/\/doi.org\/10.1038\/s41572-020-00224-3","journal-title":"Nat Rev Dis Primer"},{"key":"3322_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.radonc.2011.05.036","volume":"100","author":"P Blanchard","year":"2011","unstructured":"Blanchard P, Baujat B, Holostenco V et al (2011) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 100:33\u201340. https:\/\/doi.org\/10.1016\/j.radonc.2011.05.036","journal-title":"Radiother Oncol"},{"key":"3322_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa0802656","journal-title":"N Engl J Med"},{"key":"3322_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.seminoncol.2019.07.002","volume":"46","author":"D Alterio","year":"2019","unstructured":"Alterio D, Marvaso G, Ferrari A et al (2019) Modern radiotherapy for head and neck cancer. Semin Oncol 46:233\u2013245. https:\/\/doi.org\/10.1053\/j.seminoncol.2019.07.002","journal-title":"Semin Oncol"},{"key":"3322_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 394:1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"The Lancet"},{"key":"3322_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet 393:156\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8","journal-title":"The Lancet"},{"key":"3322_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hed.26036","volume":"42","author":"JJ Patel","year":"2020","unstructured":"Patel JJ, Levy DA, Nguyen SA et al (2020) Impact of PD-L1 expression and human papillomavirus status in anti-PD1\/PDL1 immunotherapy for head and neck squamous cell carcinoma\u2014systematic review and meta-analysis. Head Neck 42:774\u2013786. https:\/\/doi.org\/10.1002\/hed.26036","journal-title":"Head Neck"},{"key":"3322_CR8","doi-asserted-by":"publisher","first-page":"104719","DOI":"10.1016\/j.oraloncology.2020.104719","volume":"106","author":"I Brcic","year":"2020","unstructured":"Brcic I, Gallob M, Schwantzer G et al (2020) Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma. Oral Oncol 106:104719. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104719","journal-title":"Oral Oncol"},{"key":"3322_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/his.13646","volume":"73","author":"S Schneider","year":"2018","unstructured":"Schneider S, Kadletz L, Wiebringhaus R et al (2018) PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Histopathology 73:573\u2013584. https:\/\/doi.org\/10.1111\/his.13646","journal-title":"Histopathology"},{"key":"3322_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/dc.24646","volume":"49","author":"A Ambrosini-Spaltro","year":"2021","unstructured":"Ambrosini-Spaltro A, Dubini A, Pieri F et al (2021) PD-L1 expression in NSCLC: role of cell blocks and concordance between samples. Diagn Cytopathol 49:303\u2013310. https:\/\/doi.org\/10.1002\/dc.24646","journal-title":"Diagn Cytopathol"},{"key":"3322_CR11","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol 4:e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013","journal-title":"JAMA Oncol"},{"key":"3322_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara K, Zhang N, Corigliano E et al (2019) Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 143:330\u2013337. https:\/\/doi.org\/10.5858\/arpa.2018-0043-OA","journal-title":"Arch Pathol Lab Med"},{"key":"3322_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174. https:\/\/doi.org\/10.2307\/2529310","journal-title":"Biometrics"},{"key":"3322_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.oraloncology.2018.09.016","volume":"86","author":"W Yang","year":"2018","unstructured":"Yang W, Wong MCM, Thomson PJ et al (2018) The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol 86:81\u201390. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.09.016","journal-title":"Oral Oncol"},{"key":"3322_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/odi.13088","volume":"26","author":"D Lenouvel","year":"2020","unstructured":"Lenouvel D, Gonz\u00e1lez-Moles M\u00c1, Talbaoui A et al (2020) An update of knowledge on PD-L1 in head and neck cancers: physiologic, prognostic and therapeutic perspectives. Oral Dis 26:511\u2013526. https:\/\/doi.org\/10.1111\/odi.13088","journal-title":"Oral Dis"},{"key":"3322_CR16","doi-asserted-by":"publisher","first-page":"104460","DOI":"10.1016\/j.oraloncology.2019.104460","volume":"99","author":"JD Cramer","year":"2019","unstructured":"Cramer JD, Burtness B, Ferris RL (2019) Immunotherapy for head and neck cancer: recent advances and future directions. Oral Oncol 99:104460. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104460","journal-title":"Oral Oncol"},{"key":"3322_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/PAI.0000000000000941","volume":"29","author":"M Kalpakoff","year":"2021","unstructured":"Kalpakoff M, Hund S, Musser J et al (2021) Intrapatient tumor heterogeneity in IHC interpretation using PD-L1 IHC 22C3 pharmDx. Appl Immunohistochem Mol Morphol 29:667\u2013673. https:\/\/doi.org\/10.1097\/PAI.0000000000000941","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"3322_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12105-019-01097-z","volume":"14","author":"AS Paintal","year":"2020","unstructured":"Paintal AS, Brockstein BE (2020) PD-L1 CPS scoring accuracy in small biopsies and aspirate cell blocks from patients with head and neck squamous cell carcinoma. Head Neck Pathol 14:657\u2013665. https:\/\/doi.org\/10.1007\/s12105-019-01097-z","journal-title":"Head Neck Pathol"},{"key":"3322_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/cncy.22501","volume":"130","author":"Z Liu","year":"2021","unstructured":"Liu Z, Williams M, Stewart J et al (2021) Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Cancer Cytopathol 130:110\u2013119. https:\/\/doi.org\/10.1002\/cncy.22501","journal-title":"Cancer Cytopathol"},{"key":"3322_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41416-019-0449-y","volume":"120","author":"JH Rasmussen","year":"2019","unstructured":"Rasmussen JH, Lelkaitis G, H\u00e5kansson K et al (2019) Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer 120:1003\u20131006. https:\/\/doi.org\/10.1038\/s41416-019-0449-y","journal-title":"Br J Cancer"},{"key":"3322_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1159\/000515441","volume":"99","author":"N Hirshoren","year":"2021","unstructured":"Hirshoren N, Al-Kharouf I, Weinberger JM et al (2021) Spatial intratumoral heterogeneity expression of PD-L1 antigen in head and neck squamous cell carcinoma. Oncology 99:464\u2013470. https:\/\/doi.org\/10.1159\/000515441","journal-title":"Oncology"},{"key":"3322_CR22","doi-asserted-by":"publisher","first-page":"e14423","DOI":"10.7759\/cureus.14423","volume":"13","author":"M Kikuchi","year":"2021","unstructured":"Kikuchi M, Yamashita D, Hara S et al (2021) Discordant immune marker expression between preoperatively biopsied and matched surgically resected specimens in patients with oral squamous cell carcinoma. Cureus 13:e14423. https:\/\/doi.org\/10.7759\/cureus.14423","journal-title":"Cureus"},{"key":"3322_CR23","doi-asserted-by":"publisher","first-page":"153605","DOI":"10.1016\/j.prp.2021.153605","volume":"226","author":"G Paolino","year":"2021","unstructured":"Paolino G, Pantanowitz L, Barresi V et al (2021) PD-L1 evaluation in head and neck squamous cell carcinoma: insights regarding specimens, heterogeneity and therapy. Pathol - Res Pract 226:153605. https:\/\/doi.org\/10.1016\/j.prp.2021.153605","journal-title":"Pathol - Res Pract"},{"key":"3322_CR24","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jop.13220","volume":"50","author":"I Girolami","year":"2021","unstructured":"Girolami I, Pantanowitz L, Barberis M et al (2021) Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma. J Oral Pathol Med 50:864\u2013873. https:\/\/doi.org\/10.1111\/jop.13220","journal-title":"J Oral Pathol Med"},{"key":"3322_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/his.14562","volume":"80","author":"B Cerbelli","year":"2021","unstructured":"Cerbelli B, Girolami I, Eccher A et al (2021) Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. Histopathology 80:397\u2013406. https:\/\/doi.org\/10.1111\/his.14562","journal-title":"Histopathology"},{"key":"3322_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/cancers13020292","volume":"13","author":"S Crosta","year":"2021","unstructured":"Crosta S, Boldorini R, Bono F et al (2021) PD-L1 testing and squamous cell carcinoma of the head and neck: a multicenter study on the diagnostic reproducibility of different protocols. Cancers 13:292. https:\/\/doi.org\/10.3390\/cancers13020292","journal-title":"Cancers"},{"key":"3322_CR27","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","volume":"34","author":"EJ de Ruiter","year":"2020","unstructured":"de Ruiter EJ, Mulder FJ, Koomen BM et al (2020) Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol 34:1125\u20131132. https:\/\/doi.org\/10.1038\/s41379-020-0644-7","journal-title":"Mod Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03322-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T01:03:51Z","timestamp":1656032631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03322-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3322"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03322-7","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"13 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was approved by the Local Research Ethics Committee (CEROM) on Jan 22nd, 2021 (N. 2883).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}